ESR1 and cancer: The risk of death in the years 2 through 5 after diagnosis is greater for non ER+/PR+ cancers as compared to ER+/PR+.[10] To confirm this, we used the SEER database to identify 92,701 patients with a primary breast cancer diagnosed between 1993 and 1996.